Nucleic Acid Molecules for Targeted Immune Response Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy and gene therapy methods are imperfect and lack effective solutions for treating diseases, particularly in inducing immune responses against specific proteins overexpressed in cancer cells or infectious agents.
Innovation Solution
Nucleic acid molecules are designed to encode sequences for constitutive promoters, full-length proteins, linkers, ubiquitin, and protein fragments, which are operatively connected to facilitate expression and immune response induction, including the use of nuclear localization signals for efficient cellular uptake and expression of target molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunotherapy and gene therapy methods are used, then treatment of diseases is achieved, but the therapies are imperfect and lack effective solutions for inducing immune responses against specific proteins
Solution Approach 1:
The patent segments the target protein into multiple components: full-length protein, linker, ubiquitin, and protein fragments (at least 7 amino acid residues). This segmentation allows the immune system to recognize multiple epitopes simultaneously, enhancing the immune response while maintaining versatility for treating different diseases by targeting different protein segments.
Solution Approach 2:
The patent creates a composite therapeutic construct by operatively connecting multiple nucleic acid sequences that encode different protein components (full-length protein, linker, ubiquitin, fragments). This composite approach combines the advantages of each component to achieve reliable and versatile immune response induction against specific disease targets.
2Reliability
If nucleic acid molecules encode multiple components (full-length protein, linker, ubiquitin, fragments), then immune response induction is enhanced, but the molecular complexity increases
Solution Approach 1:
The patent merges multiple nucleic acid sequences into a single operatively connected construct that encodes full-length protein, linker, ubiquitin, and protein fragments. This merging simplifies delivery and expression while maintaining the complex functional benefits of multiple protein components for reliable immune response induction.
3Measurement precision
If protein fragments of at least 7 amino acid residues are included, then immune response specificity is improved, but the precision of target recognition requires higher manufacturing precision
Solution Approach 1:
The patent specifies a minimum parameter for fragment length (at least 7 amino acid residues) that optimizes immune recognition without requiring excessive manufacturing precision. This parameter change balances specificity with practical manufacturability, allowing reliable target recognition while accommodating standard molecular biology techniques.
Data Source
AI summary
Nucleic acid molecules are provided herein that can be used, for example, to treat cancer or infections, or to induce an immune response in a subject, or to deliver or express a target molecule in or from a cell.